Immunoregulatory circuits which modulate responsiveness to suppressor cell signals: characterization of an effector cell in the contrasuppressor circuit

1981 ◽  
Vol 11 (12) ◽  
pp. 973-980 ◽  
Author(s):  
Douglas R. Green ◽  
Diane D. Eardley ◽  
Art Kimura ◽  
Donal B. Murphy ◽  
Katsumi Yamauchi ◽  
...  
Keyword(s):  
Effector Cell ◽  
Suppressor Cell ◽  
Cell Signals

Characterization of Non-T Effector Cell Subpopulations Involved in Production of Human Alpha Interferon

1986 ◽  
Vol 15 (6) ◽  
pp. 559-574 ◽  
Author(s):  
Maria G Ikossi ◽  
Howard Ozer ◽  
Carel J. van Oss ◽  
Kailash C. Chadha
Keyword(s):  
Effector Cell ◽  
Alpha Interferon ◽  
Cell Subpopulations

scholarly journals Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab

Blood ◽  
2006 ◽  
Vol 108 (8) ◽  
pp. 2736-2744 ◽  
Author(s):  
Rhona Stein ◽  
Zhengxing Qu ◽  
Susan Chen ◽  
David Solis ◽  
Hans J. Hansen ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Effector Cell ◽  
Cell Functions ◽  
Hla Dr ◽  
Complement Dependent Cytotoxicity ◽  
Survival Pathway ◽  
Anti Cd20

AbstractHLA-DR is under investigation as a target for monoclonal antibody (mAb) therapy of malignancies. Here we describe a humanized IgG4 form of the anti-HLA-DR mAb L243, hL243γ4P (IMMU-114), generated to provide an agent with selectivity toward neoplastic cells that can kill without complement-dependent cytotoxicity (CDC) or antibody-dependent cellular-cytotoxicity (ADCC), so as to reduce reliance on intact immunologic systems in the patient and effector mechanism-related toxicity. In vitro studies show that replacing the Fc region of hL243γ1, a humanized IgG1 anti-HLA-DR mAb, with the IgG4 isotype abrogates the effector cell functions of the antibody (ADCC and CDC) while retaining its antigen-binding properties, antiproliferative capacity (in vitro and in vivo), and the ability to induce apoptosis concurrent with activation of the AKT survival pathway. Growth inhibition was evaluated compared with and in combination with the anti-CD20 mAb rituximab, with the combination being more effective than rituximab alone in inhibiting proliferation. Thus, hL243γ4P is indistinguishable from hL243γ1 and the parental murine mAb in assays dependent on antigen recognition. The abrogation of ADCC and CDC, which are believed to play a major role in side effects of mAb therapy, may make this antibody an attractive clinical agent. In addition, combination of hL243γ4P with rituximab offers the prospect for improved patient outcome.

Tu2002 Characterization of Myeloid - Derived Suppressor Cell Populations in Localized Rectal Adenocarcinoma Patients

2015 ◽  
Vol 148 (4) ◽  
pp. S-956-S-957
Author(s):  
Erez Hasnis ◽  
Aviva Dahan ◽  
Alexander Beny Daniel Duek ◽  
Yehuda Chowers ◽  
Elizabeth E. Half
Keyword(s):  
Rectal Adenocarcinoma ◽  
Suppressor Cell ◽  
Cell Populations ◽  
Myeloid Derived Suppressor Cell

scholarly journals Characterization of the suppressor cell activity in human cord blood lymphocytes.

1981 ◽  
Vol 68 (6) ◽  
pp. 1577-1585 ◽  
Author(s):  
M A Rodriguez ◽  
A D Bankhurst ◽  
J L Ceuppens ◽  
R C Williams
Keyword(s):  
Cord Blood ◽  
Cell Activity ◽  
Suppressor Cell ◽  
Human Cord Blood ◽  
Blood Lymphocytes ◽  
Cord Blood Lymphocytes
Sign in / Sign up

Export Citation Format

Share Document